LKPC plans to acquire equity in Hecheng Company to further optimize resource allocation
LKPC announced plans to acquire 1.9231% equity in Shandong Lukang Hecheng Pharmaceutical Co., Ltd. to optimize resource allocation and improve operational decision-making efficiency. This equity is publicly listed for transfer by the Zoucheng Economic Development Zone Management Committee at the Shandong Property Rights Exchange Center. If the transaction is successful, LKPC will directly hold 100% equity in Hecheng Company, and the scope of consolidated financial statements will remain unchanged
According to the Zhitong Finance APP, LKPC (600789.SH) announced that Shandong Lukang and Cheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Cheng Company") is a joint venture established by the company and the Management Committee of Zoucheng Economic Development Zone (hereinafter referred to as "Zoucheng Economic Development Zone Management Committee"). The Zoucheng Economic Development Zone Management Committee plans to transfer its 1.9231% equity stake (hereinafter referred to as "Target Equity") in Shandong Lukang and Cheng Pharmaceutical Co., Ltd. through a public listing at the Shandong Property Rights Exchange Center. Based on the overall strategic layout and business development needs, the company intends to bid for the Target Equity through a competitive bidding process to further optimize resource allocation and improve operational decision-making efficiency. After the completion of this transaction, the company will directly hold 100% equity in Cheng Company, and the scope of the company's consolidated financial statements will remain unchanged
